Journal of Thoracic Oncology:
doi: 10.1097/JTO.0b013e31825aae25
Submitted Abstracts

Subject Index

Free Access
Back to Top | Article Outline

A

Accelerated hyperfractionated radiotherapy, S55

Accelerated radiotherapy, S52

Activins, S39

Adenocarcinoma, S10, S26, S37, S44, S45, S71

Adjuvant chemotherapy, S52

Adrenal metastases, S14

Advanced cancer, S74

Advanced NSCLC, S19, S60, S63, S64, S66, S67, S68, S70, S72, S73, S74, S75, S77, S78

Airway obstruction, S26

Algorithm, S12

ALK, S13, S33, S46

ALK inhibitor, S64

Anaemia, S38

Angiogenesis, S40

Antiangiogenic treatment, S20

Asbestos lung burdens, S11

ATM, S42

Autofluorescence bronchoscopy, S27

Autofluorescence videobronchoscopy, S51

Back to Top | Article Outline

B

Bevacizumab, S20, S62, S72, S74

Beyond disease progression, S68

Biology, S11

Biomarker, S21, S28, S30, S34, S44, S51, S83

Biopsy, S41, S47

Bone metastases, S8, S27, S61, S78

BRAF, S23

Brain metastases, S8, S14, S71, S86

BRCA1, S31

Breast cancer, S28, S88

Breath, S51

Bronchoscopy, S46, S51

Buccal mucosa, S25

Back to Top | Article Outline

C

Cadmium, S28

Calcium, S42

Cancer, S53

Cancer research, S88

Cancer stem cells, S38

Carboplatin, S70, S73

Carcinoid, S17

Case-referent study, S50

Caucasian, S36

CAV, S80

Cell line, S46

Cerebral relapse, S54

Cetuximab, S20

Chemokine, S40, S45

Chemoprevention, S25

Chemo-radiation, S56

Chemo-radiotherapy, S24, S79, S80

Chemotherapy, S7, S11, S16, S18, S19, S69, S74, S75, S76, S77

Chest X-ray screening, S50

Chromium exposure, S44

Chronic obstructive pulmonary disease, S75

Circulating tumor cells, S32

Cisplatin, S33, S52, S82

Clinical features, S54

Clinical management, S65

Clinical trials, S68

c-MET, S23

Colorectal cancer, S87

Combined modality therapy, S24, S56

Combined modality treatment, S17

Combined treatment, S88

Complete resection, S15, S29, S52, S54

Computed tomography, S86

Concurrent radiochemotherapy, S49

Consolidation in lung cancer, S49

Continuous hyperfractionated accelerated radiotherapy (CHART), S55

Cost analysis, S68

cPLA2α, S76

Crizotinib, S33, S46, S64, S65

CSC technology, S83

CT imaging, S22

CTLA-4, S35

CXCR4, S43

Cytology, S34

Cytoreductive surgry, S11

Back to Top | Article Outline

D

Dacomitinib, S60, S67

Debio 0932, S72

Delta-like ligand, S38

Dendritic cells vaccine, S37

Denosumab, S61

Destructive radiation-induced injuries, S57

Developing country, S29, S89

Diagnosis, S11, S83

DLCO, S75

DNA damage, S42

DNA damage response, S42

DNA methylation, S31

DNA methyltransferase inhibition, S32

DNA polymerase zeta, S42

DNA repair, S32

Docetaxel, S52, S61

Dose volume histogram, S57

Dosimetric parameters, S47

Driver gene, S13, S30

Driver mutation, S22

DR-70 tumor marker, S27

Drugs, S68

Dyspnoea, S75

Back to Top | Article Outline

E

Early detection, S22, S24, S27, S31

Early diagnosis, S21, S24

Early stage lung cancer, S16, S19, S51, S53

Ebus, S12

EGFR (epidermal growth factor receptor), S10, S13, S19, S22, S35, S60, S65, S67, S68, S75

EGFR exon 20 insertions, S64

EGFR gene amplification, S10

EGFR inhibitor, S66

EGFR mutation, S13, S34, S35, S36, S62, S64, S65, S66

EGFR tyrosine kinase inhibitor, S30, S59, S68

Elderly, S7, S70, S71

Elderly patients, S56, S70

EML4-ALK, S13, S20, S29, S40, S65

EMT, S31

Endobronchial ultrasound, S12, S46

Epidemiology, S9, S35

Epithelial mesenchymal transition, S39

ERC1, S33, S64

Erlotinib, S20, S61, S63, S67, S68, S71

Erythropoietin receptor, S38

ETOP, S13

Eus, S12

Exercise capacity, S54

Exercise test, S18

Exposure response, S65

Back to Top | Article Outline

F

18F-FDG PET/CT, S11, S51

18F-FLT, S50

FFPE, S40

Fibroblast activation protein, S83

Fibroblast growth factor receptor (FGFR), S23

First-line chemotherapy, S70

First-line setting, S71

First-line therapy, S62, S72

Fluorescent in situ hybridization (FISH), S29

Folate, S76

Folate targeted agents, S63

Folic acid, S75

Follow-up, S23

Follow-up program, S21

FOXP3, S37

Free-circulating DNA, S40

Functional evaluation, S18, S56

Back to Top | Article Outline

G

Ganetespib, S46

Gefitinib, S20, S46, S68

Gemcitabine, S57, S70

Gender differences, S9, S43

Gene expresion profile, S10

Gene signature, S59

Genetic, S10

Genetic mutation, S39

Genetic polymorphism, S26

Genetic predisposition, S26

Genome, S10

Genomic profile, S31

Glutathione S-transferase, S26

Ground-glass opacity (GGO), S21

Lymph node metastases, S41, S48

Lymphoproliferative disorder, S8

Back to Top | Article Outline

H

HE4, S44

Heat shock protein 27, S51

Helical tomotherapy, S87

High-dose radiotherapy, S82

High sensitivity and specificity, S27

Histological classification, S8

Histology, S34

HRM, S36

Hsp90, S72

Hyperbaric oxygenation, S77

Hypofractionated radiotherapy, S55, S86

Hypoxia, S33

Back to Top | Article Outline

I

ID1, S33

Iloprost, S25

Immunohistochemistry, S30, S45

Immunotherapy, S37

IMRT, S82

Incident cases, S48

Induction chemotherapy, S11, S24, S49

Integrated PET/CT, S57

Intrathoracic cancer, S54

Intratumor heterogeneity, S44

Irinotecan, S80

Back to Top | Article Outline

K

Ki-67, S34, S35

KRAS mutation, S13, S23, S59, S66

KRAS wild-type, S67

Back to Top | Article Outline

L

Large cell neuroendocrine carcinoma (LCNEC), S18, S58, S77

Laser, S15

LEBS, S25

Leucocyte levels, S76

Lewis lung cancer, S38

Limited-stage SCLC, S79, S80

Lipid profile, S43

Local ablation techniques, S53

Local control, S53

Locally advanced non-small cell lung cancer, S49, S56

Local therapy, S14

Long-term survival, S62

Low BMI, S77

Lung, S17, S41, S44, S49, S86

Lung adenocarcinoma, S10, S42, S43, S53

Lung cancer, S8, S9, S10, S12, S13, S24, S26, S28, S32, S33, S37, S39, S43, S44, S46, S47, S48, S50, S53, S55, S57, S59, S68, S69, S75

Lung cancer risk, S26

Lung cancer screening, S7, S21, S25

Lung fibrosis, S82

Lung metastases, S15, S16, S86, S88

Lung perfusion, S16

Lung screening, S24

S31, S32, S33, S34, S35, S37, S38, S40, S41, S42, S43, S44, S46, S51, S52, S53, S54, S57, S58, S59, S61, S62, S64, S65, S66, S67, S70, S71, S72, S73, S74, S76, S77, S86, S87

Non-smokers, S9

Non-squamous non-small-cell lung cancer, S73

Notch, S38

Back to Top | Article Outline

O

Oligometastases, S14, S86

Oligometastatic NSCLC, S14

Oncology nurses, S89

Operable lung cancer, S55

Outcome, S87

Overall survival, S61, S76

Overview European trial, S7

Back to Top | Article Outline

M

Magnetic resonance imaging (MRI), S86

Maintenance therapy, S72

Maligant pleural effusion, S15

Malignant mesothelioma, S84, S85

Malignant pleural effusion, S47, S78

Malignant pleural mesothelioma, S34, S39, S82, S83, S84

Malignant thymoma, S81

Markers of proliferation activity, S34

Maspin, S38

Mean corpuscular volume, S74

Mediastinal staging, S8

Mediastinoscopy, S12

MEK, S23

Melatonin nitric oxide cancer, S45

Mesoporous silica nanoparticle, S76

Mesothelioma, S11, S82, S83, S84, S85

MET, S22

MET receptor, S23

Metastasectomy, S87

Metastatic lung cancer, S87

Methylenetetrahydrofolate reductase, S43

MicroRNA (miRNA), S25, S33, S83

Microvesicles, S47

Migration, S43

miR-29b, S32

Molecular biology, S9, S18

Molecular biomarker, S13

Molecular diagnostic, S13, S40

Molecular imaging, S43

Molecular pathogenesis, S10

Molecular pathology, S34

Morphology, S10

Mortality trend, S11

mTOR, S23, S77

Multi-detector CT scan, S22

Multidisciplinary, S48

Multimodality treatment, S11, S52

Multiple malignant neoplasm, S28

Multiple tumors, S15

Multivariate analysis, S58

Muscle force, S54

Muscle wasting, S68, S69

Mutation, S31, S39

Mutation frequency, S13, S35

Back to Top | Article Outline

N

Nanoarray, S51

Narrow band imaging videobronchoscopy, S51

N2 disease, S24

Neuroendocrine tumor, S17, S77

Neutrophil to lymphocyte ratio, S84

Never smokers, S9, S54

NGO, S29, S89

Nonadenocarcinoma, S60

Non-small cell lung cancer (NSCLC), S7, S13, S15, S16, S17, S18, S23, S24, S27, S29, S30,

Back to Top | Article Outline

P

p53, S44

Paclitaxel, S71

Palliative care, S89

pan-HER, S60, S67

Patient preferences, S72

Patient selection, S14

Patterns of progression, S74

Pemetrexed, S45, S70, S72, S73, S74

Pentoxifylline, S81

PERCIST, S52

Personalized medicine, S13

PET/CT, S12, S50

Phase 2, S60

Physical function, S69

Planning, S48

Plasma biomarkers, S40

Platelet factor 4, S40

Pleural effusion, S47

Pneumonectomy, S18

Polychemotherapy, S84

Polymorphism, S26, S42, S43

Pooled analysis, S29

Predictive biomarker, S10, S30, S31, S42, S59

Predictive factor, S73

Predictive marker, S20

Predictor, S36

Preneoplasia, S32

Prevalence, S36

Previously treated, S73

Prognosis, S48, S59

Prognostic biomarker, S10

Prognostic factor, S38, S76, S78, S85

Prognostic marker, S35

Prognostic value, S29

Progression-free survival (PFS), S74

Proteomics, S30, S47

PS 2, S7

p90 S6 kinase (RSK1), S23

Pulmonary Function Tests (PFTs), S18, S47, S75

Pulmonary metastasectomy, S87

Pulmonary metastases, S87

Pulmonary nodules, S51

Pulmonary surgery, S18

Pulmonary tuberculosis, S69

Pyrrolidine-2, S76

Back to Top | Article Outline

Q

Quality assurance, S36, S62

Quality of life (QOL), S89

Quantitative imaging, S22

Back to Top | Article Outline

R

Radiation-induced lung injury (RILI), S47

Radiation pneumonitis, S47, S82, S86

Radiation therapy, S42

Radiation therapy planning, S57

Radical treatment, S54

Radiofrequency, S15

Radiotherapy, S17, S19, S55, S81, S83

Raltitrexed, S82

Real-time PCR, S30

Recerptor tyrosine kinase, S37

Recombinant human erythropoietin, S38

Re-directed T cells, S83

Regsitry, S29

Regulatory T-cells, S37

Re-irradiation, S87

Relapsed SCLC, S80

Resistance, S19

Respiratory motion, S53

Respiratory symptoms, S26

Response, S64

Response evaluation, S51, S63

Risk factor, S88

Risk prediction, S21

RT-PCR, S40

Back to Top | Article Outline

S

SABR, S53

Sarcoma, S8

Sarcomatoid, S39

Sarcomatoid carcinoma, S41

SBRT, S49, S86

Screening, S35

Second line chemotherapy, S70

Second line therapy, S67, S84

Second primary cancer, S28

Segmentectomy, S48

Selective androgen receptor modulator (SARM), S69

Self-selection, S50

Sensitive EGFR mutation, S59

Sensors, S39

Sequential treatment, S61

Serum, S66

Signaling pathways, S37

Sirtuin 1, S38, S6K2, S23

S6 kinase 1 (S6K1), S23

Sleeve lobectomy, S18

Smad2 signaling, S39

Small cell lung cancer (SCLC), S17, S18, S79, S80, S81

Smoking, S28

Somatostatin analogs, S77

Sorafinib, S84

Spirometry, S75

Squamous cell carcinoma, S23, S26, S53

Src tyrosine kinase inhibitors, S32

SRM, S83

Stable disease, S63

Stage, S11, S78

Stage III, S16, S24

Stage IIIB, S78

Stage IV, S75, S76, S78

Staging, S12

Stat3, S37

Statistics, S76

Stereotactic radiotherapy, S15

Surfaceome, S83

Surgery, S9, S15, S16, S23, S58, S59, S78

Surgical intervention, S21

Surgical technique, S87

Surgical treatment, S16, S53

Survey, S72

Survival, S68, S75, S84, S85

Survival analysis, S68

Survival time, S44

Survivn, S44

Systemic treatment, S17

Back to Top | Article Outline

T

Talc pleurodesis, S78

Targeted agent, S63

Targeted approach, S11

Targeted therapy, S7

Temozolamide, S71

Thin slice CT scan, S21

Thoracic radiotherapy, S24

Thymic carcinoma, S8, S81

Thymic cell carcinoma, S81

Thymidylate synthase, S42

Thymoma, S8, S81

TKI, S64, S65, S68

TKI resistance, S22

Topotecan, S80

TP53 mutation, S44

Training, S89

Transbronchial biopsy, S47

Translational research, S30, S39

Translocation, S31

TRAP1, S27

Treatment, S16, S58

Treatment modalities, S16

Treatment modalities stage III NSCLC, S16

Trial design, S15

TTF-1, S79

T-type, S42

Tubercular pleural effusion, S69

Tubulin, S33

Tumor growth, S23

Tumor lymphocyte infiltration, S29

Tumor margins, S53

Back to Top | Article Outline

U

Urokinase-type plasminogen activator (uPA), S41

User involvement, S88

Back to Top | Article Outline

V

VEGF-TKI, S20

Video-assisted thoracic surgery (VATS), S12, S15

Video-assisted thoracic surgery (VATS) lobectomy, S12, S22

Vimentin, S41

Vinorelbine, S46

Vitamin B12, S75

VMAT-FFF, S49, S86

Volatile organic compounds, S39, S51

Back to Top | Article Outline

W

WFDC2, S44

Back to Top | Article Outline

X

Xenobiotic biotransformation enzymes, S26

Back to Top | Article Outline

Z

Zoledronic acid, S61, S78

© 2012International Association for the Study of Lung Cancer

Login

Article Tools

Share

Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.